Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del)-Reference-Cited by-同舟云学术

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del)

Published:2020-12-17 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Southern Kevin W¹,Murphy Jared¹,Sinha Ian P¹,Nevitt Sarah J²

Affiliation:

1. Department of Women's and Children's Health; University of Liverpool; Liverpool UK

2. Department of Biostatistics; University of Liverpool; Liverpool UK

Publisher

Wiley

Subject

Pharmacology (medical)

Reference234 articles.

1. Lumacaftor, an investigational CFTR corrector, in combination with ivacaftor, a CFTR potentiator, in CF patients with the F508del-CFTR mutation: phase 2 interim analysis;Boyle;Journal of Cystic Fibrosis,2013

2. The investigational CFTR corrector, VX-809 (lumacaftor) co-administered with the oral potentiator ivacaftor improved CFTR and lung function in F509-8DEL homozygous patients: phase II study results;Boyle;Pediatric Pulmonology,2012

3. VX-809, an investigational CFTR corrector, in combination with VX-770, an investigational CFTR potentiator, in subjects with CF and homozygous for the F508DEL-CFTR Mutation;Boyle;Pediatric Pulmonology,2011

4. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: A phase 2 randomised controlled trial;Boyle;Lancet. Respiratory Medicine,2014

5. Supplementary Appendix to "A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: A phase 2 randomised controlled trial.";Boyle;Lancet. Respiratory Medicine,2014

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reported Adverse Events in a Multicenter Cohort of Patients Ages 6-18 Years with Cystic Fibrosis and at Least One F508del Allele Receiving Elexacaftor/Tezacaftor/Ivacaftor;The Journal of Pediatrics;2024-11

2. Advances in Care and Outcomes for Children with Cystic Fibrosis;Clinics in Chest Medicine;2024-09

3. Highly branched poly β-amino ester/CpG-depleted CFTR plasmid nanoparticles for non-viral gene therapy in lung cystic fibrosis disease;Molecular Therapy - Methods & Clinical Development;2024-09

4. Silibinins and curcumin as promising ligands against mutant cystic fibrosis transmembrane regulator protein;AMB Express;2024-07-23

5. Effectiveness and safety of elexacaftor/tezacaftor/ivacaftor treatment in children aged 6‐11 years with cystic fibrosis in a real‐world setting;Pediatric Pulmonology;2024-06-13